Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  venetoclax
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BO25323, NCI-2015-00926, 2014-001810-24, NCT02242942
Bcl-2 inhibitor GDC-0199 in Combination with Obinutuzumab and Ibrutinib in Treating Patients with Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14266, NCI-2015-00252, ML29533, NCT02427451
A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29833, NCI-2015-02093, 2015-001998-40, NCT02611323
A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO28440, NCI-2013-01974, 2012-002351-42, NCT01671904
A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28331, NCI-2013-01154, 2012-002038-34, NCT01685892
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: M12-901, NCI-2013-01756, 2011-004626-10, NCT01794507
Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773
A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: M14-387, NCI-2015-00216, 2014-002610-23, NCT02287233
Start Over